CD177 and cancer: TNFRSF18, also known as glucocorticoid-induced TNF receptor (GITR), a cell surface receptor expressed by immune cells (mainly Tregs), acts as a key regulator in inflammatory and immune responses [27] and is an emerging molecular target in cancer immunotherapy [28, 29].